Health Care Providers (HCPs) in the endocrinology specialty setting are challenged to be knowledgeable of the pathophysiology of MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) and its associated risk factors, as well as feel confident around how and when to order noninvasive diagnostic tests to prevent the emergence of more severe complications and stay on top of current guidelines and emerging treatment options.
Explore this interactive learning format, Build Your Own Case Study (BYOCS), titled Redefining MASLD/MASH Care: Personalized Strategies for Assessment, Diagnosis and Management.
This collaborative effort, in conjunction with Global Liver Institute, provides expert guidance and clinical best practices for identifying comorbidities and risk factors for clinically significant fibrosis, understanding the role of non-invasive testing and risk stratification, and describing and evaluating current guidelines and emerging therapies for the management of MASLD/MASH.
By participating in this activity, you will gain valuable insights into effectively addressing MASLD/MASH for improved patient health.
Speakers
Jay H. Shubrook, DO, FACOFP, FAAFP
Jay H. Shubrook, DO is a Board-Certified family physician and a Fellowship trained Diabetologist. He is a Professor at Touro University California where he also serves as the Director of Diabetes Services. His research focus is on the prevention and early intervention for type 2 diabetes. He clinical and professional focus is on better training the primary care workforce to be prepared to help people manage diabetes. He is the Associate Editor of Clinical Diabetes and is the Chair of the Board of the American College of Diabetology. He was honored to serve on the AGA steering and writing committee for the NASH: A call to action guidelines for evaluation and treatment of NASH.
Naim Alkhouri, MD, FAASLD, ABOM
Chief Medical Officer
Director of the Steatotic Liver Program
Arizona Liver Health
Phoenix, AZ, USA
Naim Alkhouri, M.D., is the Chief Medical Officer (CMO), Chief of Transplant Hepatology, and Director of the Steatotic Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Dr. Alkhouri is also the medical director of research at the Clinical Research Institute of Ohio (CRIOH) and the director of the Steatotic Liver Program at Northshore Gastroenterology and Endoscopy in Westlake, OH.
Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatric at the University of Texas (UT) Health in San Antonio, TX.
Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the Cleveland Clinic in Cleveland, OH where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute.
Dr. Alkhouri is a key opinion leader in the field of MASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global MASH trials and a member of the AASLD MASLD Special Interest Group (MASLD SIG).
Dr. Alkhouri has been published in over 250 publications to include publications in the New England Journal of Medicine, Lancet, JAMA, Nature Medicine, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his work at both national and international medical conferences.
Sonal Kumar, MD, MPH
Assistant Professor of Medicine
Director of Clinical Gastroenterology and Hepatology
Weill Cornell Medical College
New York, NY, USA
Dr. Sonal Kumar graduated summa cum laude from Washington University in St. Louis in 2002 and obtained her medical degree in 2006 from Washington University School of Medicine. She subsequently completed internal medicine internship and residency at Barnes-Jewish Hospital - Washington University School of Medicine and then Gastroenterology and Hepatology fellowship at Brigham and Women’s Hospital - Harvard University. During fellowship, she also received her Master of Public Health from the Harvard School of Public Health. Dr. Kumar is board certified in Internal Medicine and Gastroenterology/Hepatology.
Dr. Kumar is an Assistant Professor of Medicine and currently is the Director of Clinical Hepatology at Weill Cornell Medical College. Her clinical interests include non-alcoholic fatty liver disease, viral hepatitis, genetic/autoimmune liver disease and alcoholic liver disease. Dr. Kumar also has a background in clinical research and is involved in multiple clinical trials. She is a member of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, the Empire Liver Foundation, and the American College of Gastroenterology. Dr. Kumar also routinely performs upper endoscopy and colonoscopy.
Accreditation and Disclosure Information
Target Audience
This educational activity is designed for endocrinologists, diabetologists, fellows, NPs, PAs, and other healthcare professionals involved in caring for individuals with or at risk for MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease) in the endocrinology specialty setting in the U.S.
Educational Objective
After completing this CE activity, the participant should be better able to:
- Review the metabolic risk factors and screening criteria to identify and stratify patients at risk for MASLD/MASH.
- Describe how and when to use non-invasive diagnostics to diagnose, stage, and monitor progress/response in MASLD/MASH.
- Define current guidelines and care pathways for therapeutic options tailored to patient stage of disease, risk factors, comorbidities, preferences, capabilities, and circumstances.
- Evaluate the efficacy of emerging pharmacologic therapies in the medical management of MASLD/MASH.
Agenda
- Introduction
- MASLD/MASH and Comorbidities: Factors for Identifying High-Risk Patients
- The connection between MASLD/MASH, obesity, and T2D
- MASLD/MASH Diagnosis: Non-Invasive Testing and Risk Stratification
- The importance of early detection and intervention in MASLD/MASH
- Risk management and stratification in endocrine specialty setting
- Current & Emerging Treatment Approaches for MASLD/MASH
- Guideline directed treatment approaches: lifestyle management role of weight reduction, antiobesity, and antidiabetic medications
- Emerging therapies
- Conclusions
This activity is provided by MLI in collaboration with Global Liver Institute
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
PA
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 12, 2025. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.33 contact hour in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Support Statement
This activity is supported by an educational grant from Novo Nordisk Inc.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. and Global Liver Institute are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner/Presenter
Jay H. Shubrook, DO, FACOFP, FAAFP
Professor Primary Care Department
Diabetologist
Touro University California
College Osteopathic Medicine
Vallejo, CA, USA
Jay H. Shubrook, DO, FACOFP, FAAFP, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Abbott, Bayer, Eli Lilly, Madrigal, Novo Nordisk
The following relationships have ended within the last 24 months:
Consultant/Advisor: Nevro (ended 6/2023)
Planner/Presenter
Naim Alkhouri, MD, FAASLD, ABOM
Chief Medical Officer
Director of the Steatotic Liver Program
Arizona Liver Health
Phoenix, AZ, USA
Naim Alkhouri, MD, FAASLD, ABOM, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: 89bio, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept, Ipsen, Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, and Zydus.
Speakers’ Bureau: AbbVie, Alexion, Echosens, Eisai, Gilead, Intercept, Ipsen, Madrigal, Perspectum, Salix, and Theratechnologies
Research funding: 89bio, Akero, Arbutus, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, CymaBay, DSM, Galectin, Genentech, Genfit, Gilead, Hepagene, Healio, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, Zydus
Planner/Presenter
Sonal Kumar, MD, MPH
Assistant Professor of Medicine
Director of Clinical Gastroenterology and Hepatology
Weill Cornell Medical College
New York, NY, USA
Sonal Kumar, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Novo Nordisk, Madrigal, Gilead, Ipsen, CymaBay, Intercept
Speakers’ Bureau: Ipsen, Gilead, Madrigal, Intercept
Research Funding: Novo Nordisk, Gilead, Akero, Ipsen, CymaBay, Intercept, Galectin
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
About This Activity
Medical Learning Institute, Inc. and Global Liver Institute are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grant subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute, Inc | All Rights Reserved